Life Sciences M&A Tops $240 Billion in 2019

Life Sciences M&A Tops $240 Billion in 2019

Analysis | M&A Life Sciences M&A Tops $240 Billion in 2019 This article is a sample from the DealForma Annual Deal Trends Report provided to database subscribers. Data for this analysis was compiled using the DealForma biopharma deals database. We applied...
Cancer Cell Therapy M&A

Cancer Cell Therapy M&A

Analysis | M&A Cancer Cell Therapy M&A Over the last three years, there have been eight cancer cell therapy M&A deals for advanced first generation and next gen cancer cell therapy companies. Six of them have been completed to date. Data for this analysis...
Reverse Mergers in Biopharma

Reverse Mergers in Biopharma

Analysis | M&A Reverse Mergers in Biopharma Reverse mergers have been a relatively quick method for companies to gain a public listing as an alternative to IPOs. A private company looking to go public merges with a company that is already publicly traded and...